The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer
Backgrounds: The effectiveness of oral antiviral therapy including nirmatrelvir plus ritonavir and molnupiravir in managing COVID-19 among individuals with pre-existing lung cancer was unclear. Therefore, this study was conducted to evaluate the usefulness of antiviral agents in the management of CO...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2024-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a5bb6ec155a64b53b0d60d1f36d4ac49 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Wan-Hsuan Hsu |e author |
| 700 | 1 | 0 | |a Bo-Wen Shiau |e author |
| 700 | 1 | 0 | |a Ya-Wen Tsai |e author |
| 700 | 1 | 0 | |a Jheng-Yan Wu |e author |
| 700 | 1 | 0 | |a Po-Yu Huang |e author |
| 700 | 1 | 0 | |a Min-Hsiang Chuang |e author |
| 700 | 1 | 0 | |a Ting-Hui Liu |e author |
| 700 | 1 | 0 | |a Chih-Cheng Lai |e author |
| 700 | 1 | 0 | |a Tzu-Chieh Weng |e author |
| 245 | 0 | 0 | |a The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer |
| 260 | |b Elsevier, |c 2024-08-01T00:00:00Z. | ||
| 500 | |a 1876-0341 | ||
| 500 | |a 10.1016/j.jiph.2024.05.053 | ||
| 520 | |a Backgrounds: The effectiveness of oral antiviral therapy including nirmatrelvir plus ritonavir and molnupiravir in managing COVID-19 among individuals with pre-existing lung cancer was unclear. Therefore, this study was conducted to evaluate the usefulness of antiviral agents in the management of COVID-19 among patients with lung cancer. Methods: Utilizing data from the TriNetX - a global health research network, a retrospective cohort study was conducted involving 2484 patients diagnosed with both lung cancer and COVID-19. Propensity score matching (PSM) was employed to create well-balanced cohorts. The study assessed the primary outcome of all-cause hospitalization or mortality within a 30-day follow-up. Results: After PSM, the oral antiviral group exhibited a significantly lower risk of the primary composite outcome compared to the control group (6.1 % vs. 9.9 %; HR: 0.60; 95 % CI: 0.45-0.80). This association was consistent across various subgroups according to age, sex, vaccine status, type of oral antiviral agent, and lung cancer characteristics. Additionally, the oral antiviral group showed a lower risk of all-cause hospitalization (HR: 0.73; 95 % CI: 0.54-0.99) and a significantly lower risk of mortality (HR: 0.16; 95 % CI: 0.06-0.41). Conclusion: The study suggests a favorable impact of oral antiviral therapy on the outcomes of COVID-19 in individuals with lung cancer and support the potential utility of oral antiviral agents in improving outcomes in this vulnerable population. | ||
| 546 | |a EN | ||
| 690 | |a COVID-19 | ||
| 690 | |a Molnupiravir | ||
| 690 | |a Nirmatrelvir plus ritonavir | ||
| 690 | |a SARS-CoV-2 | ||
| 690 | |a Infectious and parasitic diseases | ||
| 690 | |a RC109-216 | ||
| 690 | |a Public aspects of medicine | ||
| 690 | |a RA1-1270 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of Infection and Public Health, Vol 17, Iss 8, Pp 102465- (2024) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S1876034124001989 | |
| 787 | 0 | |n https://doaj.org/toc/1876-0341 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a5bb6ec155a64b53b0d60d1f36d4ac49 |z Connect to this object online. |